LSD1/HDAC6-IN-2

LSD1/HDAC6-IN-2

• CAS Number: 2982787-50-6
• UNSPSC Description: LSD1/HDAC6-IN-2 (JBI-802) is an orally active LSD1/HDAC6/MAO-A inhibitor, with IC50 values of 5 nM, 11 nM, and 5 nM, respectively. LSD1/HDAC6-IN-2 can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226. LSD1/HDAC6-IN-2 can be used for research on diseases such as acute myeloid leukemia and lymphoma[1][2].
• Target Antigen: HDAC; Histone Demethylase; Monoamine Oxidase
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage;Epigenetics;Neuronal Signaling
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/lsd1-hdac6-in-2.html
• Solubility: DMSO : ≥ 100 mg/mL
• Smiles: ONC(C(C=C1)=CC=C1CN(N=C2)C=C2CN[C@H]3[C@H](C4=CC=CC=C4)C3)=O.[H]Br
• Molecular Weight: 443.34
• References & Citations: [1]Yang X. Research progress of LSD1-based dual-target agents for cancer therapy. Bioorg Med Chem. 2024 Mar 1;101:117651. |[2]Sivanandhan D, et al. JBI-802, novel dual inhibitor of LSD1-HDAC6 for treatment of cancer[J]. Cancer Research, 2020, 80(16_Supplement): 1756-1756.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported